Prescription drug monitoring program data tracking of opioid addiction treatment outcomes in integrated dual diagnosis care involving injectable naltrexone

Ayesha Sajid, Aaron Whiteman, Richard Bell, Marion S. Greene, Eric Engleman, R. Chambers

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background and Objectives: Fourfold increases in opioid prescribing and dispensations over 2 decades in the U.S. has paralleled increases in opioid addictions and overdoses, requiring new preventative, diagnostic, and treatment strategies. This study examines Prescription Drug Monitoring Program (PDMP) tracking as a novel measure of opioid addiction treatment outcomes in a university-affiliated integrated mental health-addiction treatment clinic. Methods: Repeated measure parametrics examined PDMP and urine drug screening (UDS) data before and after first injection for all patients (N = 68) who received at least one long-acting naltrexone injection (380 mg/IM) according to diagnostic groupings of having either (i) alcohol (control); (ii) opioid; or (iii) combined alcohol and opioid use disorders. Results: There were no group differences post-injection in treatment days, injections delivered, or treatment service encounters. UDS and PDMP measures of opioid exposures were greater in opioid compared to alcohol-only patients. Post-first injection, UDS's positive for opioids declined (p <.05) along with PDMP measures of opioid prescriptions (p <.001), doses (p <.01), types (p <.001), numbers of dispensing prescribers (p <.001) and pharmacies (p <.001). Opioid patients without alcohol disorders showed the best outcomes with 50% to 80% reductions in PDMP-measures of opioids, down to levels of alcohol-only patients. Conclusions: This study shows PDMP utility for measuring opioid addiction treatment outcomes, supporting the routine use of PDMPs in clinical and research settings. Scientific Significance: These findings demonstrate that opioid addiction in patients with complex addictions and mental illnesses comorbidities can show effective treatment responses as measured by PDMP tracking of decreases in opioid prescriptions to those patients. (Am J Addict 2016;25:557–564).

Original languageEnglish (US)
Pages (from-to)557-564
Number of pages8
JournalAmerican Journal on Addictions
Volume25
Issue number7
DOIs
StatePublished - Oct 1 2016

Fingerprint

Dual (Psychiatry) Diagnosis
Naltrexone
Prescription Drugs
Drug Monitoring
Opioid Analgesics
Injections
Alcohols
Preclinical Drug Evaluations
Prescriptions
Urine
Therapeutics
Drug Prescriptions
Pharmacies

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

@article{aab7f6458a0848c2ba9ab420d26ceeda,
title = "Prescription drug monitoring program data tracking of opioid addiction treatment outcomes in integrated dual diagnosis care involving injectable naltrexone",
abstract = "Background and Objectives: Fourfold increases in opioid prescribing and dispensations over 2 decades in the U.S. has paralleled increases in opioid addictions and overdoses, requiring new preventative, diagnostic, and treatment strategies. This study examines Prescription Drug Monitoring Program (PDMP) tracking as a novel measure of opioid addiction treatment outcomes in a university-affiliated integrated mental health-addiction treatment clinic. Methods: Repeated measure parametrics examined PDMP and urine drug screening (UDS) data before and after first injection for all patients (N = 68) who received at least one long-acting naltrexone injection (380 mg/IM) according to diagnostic groupings of having either (i) alcohol (control); (ii) opioid; or (iii) combined alcohol and opioid use disorders. Results: There were no group differences post-injection in treatment days, injections delivered, or treatment service encounters. UDS and PDMP measures of opioid exposures were greater in opioid compared to alcohol-only patients. Post-first injection, UDS's positive for opioids declined (p <.05) along with PDMP measures of opioid prescriptions (p <.001), doses (p <.01), types (p <.001), numbers of dispensing prescribers (p <.001) and pharmacies (p <.001). Opioid patients without alcohol disorders showed the best outcomes with 50{\%} to 80{\%} reductions in PDMP-measures of opioids, down to levels of alcohol-only patients. Conclusions: This study shows PDMP utility for measuring opioid addiction treatment outcomes, supporting the routine use of PDMPs in clinical and research settings. Scientific Significance: These findings demonstrate that opioid addiction in patients with complex addictions and mental illnesses comorbidities can show effective treatment responses as measured by PDMP tracking of decreases in opioid prescriptions to those patients. (Am J Addict 2016;25:557–564).",
author = "Ayesha Sajid and Aaron Whiteman and Richard Bell and Greene, {Marion S.} and Eric Engleman and R. Chambers",
year = "2016",
month = "10",
day = "1",
doi = "10.1111/ajad.12441",
language = "English (US)",
volume = "25",
pages = "557--564",
journal = "American Journal on Addictions",
issn = "1055-0496",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Prescription drug monitoring program data tracking of opioid addiction treatment outcomes in integrated dual diagnosis care involving injectable naltrexone

AU - Sajid, Ayesha

AU - Whiteman, Aaron

AU - Bell, Richard

AU - Greene, Marion S.

AU - Engleman, Eric

AU - Chambers, R.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Background and Objectives: Fourfold increases in opioid prescribing and dispensations over 2 decades in the U.S. has paralleled increases in opioid addictions and overdoses, requiring new preventative, diagnostic, and treatment strategies. This study examines Prescription Drug Monitoring Program (PDMP) tracking as a novel measure of opioid addiction treatment outcomes in a university-affiliated integrated mental health-addiction treatment clinic. Methods: Repeated measure parametrics examined PDMP and urine drug screening (UDS) data before and after first injection for all patients (N = 68) who received at least one long-acting naltrexone injection (380 mg/IM) according to diagnostic groupings of having either (i) alcohol (control); (ii) opioid; or (iii) combined alcohol and opioid use disorders. Results: There were no group differences post-injection in treatment days, injections delivered, or treatment service encounters. UDS and PDMP measures of opioid exposures were greater in opioid compared to alcohol-only patients. Post-first injection, UDS's positive for opioids declined (p <.05) along with PDMP measures of opioid prescriptions (p <.001), doses (p <.01), types (p <.001), numbers of dispensing prescribers (p <.001) and pharmacies (p <.001). Opioid patients without alcohol disorders showed the best outcomes with 50% to 80% reductions in PDMP-measures of opioids, down to levels of alcohol-only patients. Conclusions: This study shows PDMP utility for measuring opioid addiction treatment outcomes, supporting the routine use of PDMPs in clinical and research settings. Scientific Significance: These findings demonstrate that opioid addiction in patients with complex addictions and mental illnesses comorbidities can show effective treatment responses as measured by PDMP tracking of decreases in opioid prescriptions to those patients. (Am J Addict 2016;25:557–564).

AB - Background and Objectives: Fourfold increases in opioid prescribing and dispensations over 2 decades in the U.S. has paralleled increases in opioid addictions and overdoses, requiring new preventative, diagnostic, and treatment strategies. This study examines Prescription Drug Monitoring Program (PDMP) tracking as a novel measure of opioid addiction treatment outcomes in a university-affiliated integrated mental health-addiction treatment clinic. Methods: Repeated measure parametrics examined PDMP and urine drug screening (UDS) data before and after first injection for all patients (N = 68) who received at least one long-acting naltrexone injection (380 mg/IM) according to diagnostic groupings of having either (i) alcohol (control); (ii) opioid; or (iii) combined alcohol and opioid use disorders. Results: There were no group differences post-injection in treatment days, injections delivered, or treatment service encounters. UDS and PDMP measures of opioid exposures were greater in opioid compared to alcohol-only patients. Post-first injection, UDS's positive for opioids declined (p <.05) along with PDMP measures of opioid prescriptions (p <.001), doses (p <.01), types (p <.001), numbers of dispensing prescribers (p <.001) and pharmacies (p <.001). Opioid patients without alcohol disorders showed the best outcomes with 50% to 80% reductions in PDMP-measures of opioids, down to levels of alcohol-only patients. Conclusions: This study shows PDMP utility for measuring opioid addiction treatment outcomes, supporting the routine use of PDMPs in clinical and research settings. Scientific Significance: These findings demonstrate that opioid addiction in patients with complex addictions and mental illnesses comorbidities can show effective treatment responses as measured by PDMP tracking of decreases in opioid prescriptions to those patients. (Am J Addict 2016;25:557–564).

UR - http://www.scopus.com/inward/record.url?scp=84988458420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988458420&partnerID=8YFLogxK

U2 - 10.1111/ajad.12441

DO - 10.1111/ajad.12441

M3 - Article

VL - 25

SP - 557

EP - 564

JO - American Journal on Addictions

JF - American Journal on Addictions

SN - 1055-0496

IS - 7

ER -